Share This Article:
Letter to the Editor

Development of Small Molecules Activating TRAIL Apoptosis Pathway for Cancer Therapies

DOI: 10.4236/ojapo.2013.24008    4,052 Downloads   8,151 Views  


Development of Small Molecules Activating TRAIL Apoptosis Pathway for Cancer Therapies

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Bellail and C. Hao, "Development of Small Molecules Activating TRAIL Apoptosis Pathway for Cancer Therapies," Open Journal of Apoptosis, Vol. 2 No. 4, 2013, pp. 48-50. doi: 10.4236/ojapo.2013.24008.


[1] E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N., Fiore and B. Williamson, “An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 72, No. 9, 1975, pp. 3666-3670.
[2] A. C Bellail, L. Qi, P. Mulligan, V. Chhabra and C. Hao, “TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges,” Reviews on Recent Clinical Trials, Vol. 4, No. 1, 2009, pp. 34-41.
[3] K. J. Tracey, B. Beutler, S. F. Lowry, J. Merryweather, S Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey 3rd, A. Zentella, J. D. Albert, et al., “Shock and Tissue Injury Induced by Recombinant Human Cachectin,” Science, Vol. 234, No. 4775, 1986, pp. 470-474.
[4] J. Ogasawara, R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata, “Lethal Effect of the Anti-Fas Antibody in Mice,” Nature, Vol. 364, No. 6440, 1993, pp. 806-809.
[5] S. R. Wiley, K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, et al., “Identification and Characterization of a New Member of the TNF Family That Induces Apoptosis,” Immunity, Vol. 3, No. 6, 1995, pp. 673-682.
[6] R. M. Pitti, S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore and A. Ashkenazi, “Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family,” The Journal of Biological Chemistry, Vol. 271, No. 22, 1996, pp. 12687-12690.
[7] D. Lawrence, Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, et al., “Differential Hepatocyte Toxicity of Recombinant Apo2L/TRAIL Versions,” Nature Medicine, Vol. 7, No. 4, 2001, pp. 383-385.
[8] C. Hao, J. H. Song, B. Hsi, J. Lewis, D. K. Song, K. C. Petruk, D. L. Tyrrell and N. M. Kneteman, “TRAIL Inhibits Tumor Growth But Is Nontoxic to Human Hepatocytes in Chimeric Mice,” Cancer Research, Vol. 64, No. 23, 2004, pp. 8502-8506.
[9] M. J. Smyth, K. Takeda, Y. Hayakawa, J. J. Peschon, M. R. van den Brink and H. Yagita, “Nature’s TRAIL—On a Path to Cancer Immunotherapy,” Immunity, Vol. 18, No. 1, 2003, pp. 1-6.
[10] S. S. Cha, M. S. Kim, Y. H. Choi, B. J. Sung, N. K. Shin, H. C. Shin, Y. C. Sung and B. H. Oh, “2.8 ? Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity,” Immunity, Vol. 11, No. 2, 1999, pp. 253-261.
[11] R. S. Herbst, S. G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P. J. O’Dwyer, M. S. Gordon, W. Novotny, M. A. Goldwasser, T. M. Tohnya, B. L. Lum, et al., “Phase I Dose-Escalation Study of Recombinant Human Apo2L/ TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients with Advanced Cancer,” Journal of Clinical Oncology, Vol. 28, No. 17, 2010, pp. 2839-2846.
[12] J. C. Soria, E. Smit, D. Khayat, B. Besse, X. Yang, C. P. Hsu, D. Reese, J. Wiezorek and F. Blackhall, “Phase 1b Study of Dulanermin (Recombinant Human Apo2L/ TRAIL) in Combination with Paclitaxel, Carboplatin, and Bevacizumab in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 28, No. 9, 2010, pp. 1527-1533.
[13] J. C. Soria, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, J. L. Pujol, J. Kozielski, N. Baker, D. Smethurst, et al., “Randomized Phase II Study of Dulanermin in Combination with Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 29, No. 33, 2011, pp. 4442-4451.
[14] K. Ichikawa, W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, et al., “Tumoricidal Activity of a Novel Anti-Human DR5 Monoclonal Antibody without Hepatocyte Cytotoxicity,” Nature Medicine, Vol. 7, No. 8, 2001, pp. 954-960.
[15] A. Yada, M. Yazawa, S. Ishida, H. Yoshida, K. Ichikawa, S. Kurakata and K. Fujiwara, “A Novel Humanized Anti-Human Death Receptor 5 Antibody CS-1008 Induces Apoptosis in Tumor Cells without Toxicity in Hepatocytes,” Annals of Oncology, Vol. 19, No. 6, 2008, pp. 1060-1067.
[16] A. Forero-Torres, J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, F. R. Luo, S. Wojtowicz-Praga, I. Percent, and M. Saleh, “Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5),” Cancer Biotherapy & Radiopharmaceuticals, Vol. 25, No. 1, 2010, pp. 13-19.
[17] R. C. Humphreys and W. Halpern, “Trail Receptors: Targets for Cancer Therapy,” Advances in Experimental Medicine and Biology, Vol. 615, 2008, pp. 127-158.
[18] A. W. Tolcher, M. Mita, N. J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, M. Hill, T. Mays, T. McCoy, N. L. Fox, et al., “Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody with Agonist Activity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor-1,” Journal of Clinical Oncology, Vol. 25, No. 28, 2007, pp. 1390-1395.
[19] R. Plummer, G. Attard, S. Pacey, L. Li, A. Razak, R. Perrett, M. Barrett, I. Judson, S. Kaye, N. L. Fox, et al., “Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers,” Clinical Cancer Research, Vol. 13, No. 20, 2007, pp. 6187-6194.
[20] D. R. Camidge, R. S. Herbst, M. S. Gordon, S. G. Eckhardt, R. Kurzrock, B. Durbin, J. Ing, T. M. Tohnya, J. Sager, A. Ashkenazi, et al., “A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies,” Clinical Cancer Research, Vol. 16, No. 4, 2010, pp. 1256-1263.
[21] F. A Greco, P. Bonomi, J. Crawford, K. Kelly, Y. Oh, W. Halpern, L. Lo, G. Gallant and J. Klein, “Phase 2 Study of Mapatumumab, a Fully Human Agonistic Monoclonal Antibody Which Targets and Activates the TRAIL Receptor-1, in Patients with Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Vol. 61, No. 1, 2008, pp. 82-90.
[22] T. Trarbach, M. Moehler, V. Heinemann, C. H. Kohne, M. Przyborek, C. Schulz, V. Sneller, G. Gallant and S. Kanzler, “Phase II Trial of Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets and Activates the Tumour Necrosis Factor Apoptosis-Inducing Ligand Receptor-1 (TRAIL-R1), in Patients with Refractory Colorectal Cancer,” British Journal of Cancer, Vol. 102, No. 3, 2010, pp. 506-512.
[23] J. E. Allen, G. Krigsfeld, P. A. Mayes, L. Patel, D. T. Dicker, A. S. Patel, N. G. Dolloff, E. Messaris, K. A. Scata, W. Wang, et al., “Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects,” Science Translational Medicine, Vol. 5, No. 171, 2013, p.171ra17.
[24] G. Wang, X. Wang, H. Yu, S. Wei, N. Williams, D. L. Holmes, R. Halfmann, J. Naidoo, L. Wang, L. Li, et al., “Small-Molecule Activation of the TRAIL Receptor DR5 in Human Cancer Cells,” Nature Chemical Biology, Vol. 9, 2013, pp. 84-89.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.